NCT02289378

Dose-dense Biweekly Docetaxel, Oxaliplatin and 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, phase II study to evaluate the efficacy and safety of biweekly docetaxel, Oxaliplatin and de Gramont regimen on unresectable gastric adenocarcinoma in the first-line therapy.

Detailed description

Docetaxel 50mg/m2 Oxaliplatin 85mg/m2 5-Fu 2800mg/m2 Repeated every two weeks

Conditions

• Docetaxel, Oxaliplatin and Fluorouracil

Interventions

Type	Name	Description
DRUG	Docetaxel, Oxaliplatin and 5-Fu	To investigate the triplet regimen in the first-line therapy of advanced chemotherapy

Timeline

• Start date: 2014-11-01
• Primary completion: 2016-10-01
• Completion: 2017-10-01
• First posted: 2014-11-13
• Last updated: 2014-11-14

Locations

1 site across 1 country: China